Angiotensin-neprilysin inhibition in acute decompensated heart failure
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown. METHODS: We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure at 129 sites in the United States. After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or enalapril (target dose, 10 mg twice daily). The primary efficacy outcome was the time-averaged proportional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline through weeks 4 and 8. Key safety outcomes were the rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema. RESULTS: Of the 881 patients who underwent randomization, 440 were assigned to receive sacubitril-valsartan and 441 to receive enalapril. The time-averaged reduction in the NT-proBNP concentration was significantly greater in the sacubitril-valsartan group than in the enalapril group; the ratio of the geometric mean of values obtained at weeks 4 and 8 to the baseline value was 0.53 in the sacubitril-valsartan group as compared with 0.75 in the enalapril group (percent change, -46.7% vs. -25.3%; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001). The greater reduction in the NT-proBNP concentration with sacubitril-valsartan than with enalapril was evident as early as week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85). The rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. CONCLUSIONS: Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril-valsartan therapy led to a greater reduction in the NT-proBNP concentration than enalapril therapy. Rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. (Funded by Novartis; PIONEER-HF ClinicalTrials.gov number, NCT02554890 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, one-third of patients enrolled did not have a history of HF and just more than half had no previous ACEI or ARB use.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In-hospital initiation of sacubitril-valsartan resulted in a significantly greater proportional reduction in NT-proBNP compared with enalapril at weeks 4 and from baseline (mean time-averaged change in NT-proBNP, −46.7% vs 25.3%).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“This change was consistent across all subgroups, including those without previous HF and those who were RASi-naive.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In the PIONEER-HF study it was noted that in patients admitted with acute decompensated HF and reduced ejection fraction, 65% had a history of HF but only 10% were receiving an MRA at the time of admission.8”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
The Global Health and Economic Burden of Hospitalizations for Heart Failure
Ambrosy, A. P., Fonarow, G. C., Butler, J., Chioncel, O., Greene, S. J., Vaduganathan, M., Nodari, S., Lam, C. S. P., Sato, N., Shah, A. N., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.053 · Cited by 2,046
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft052 · Cited by 457
Senni, M., McMurray, J. J. V., Wachter, R., McIntyre, H. F., Reyes, A., Majercak, I., Andreka, P., Shehova-Yankova, N., Anand, I., Yilmaz, M. B., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.548 · Cited by 236
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Ambrosy, A. P., Duffy, C. I., McCague, K., Hernandez, A. F., Rocha, R. A., & Braunwald, E. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.004 · Cited by 76
Self-citationAmbrosy, A. P., Mentz, R. J., Fiuzat, M., Cleland, J. G. F., Greene, S. J., O’Connor, C. M., Teerlink, J. R., Zannad, F. M., & Solomon, S. D. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1159 · Cited by 57
Self-citation
Cited by
Items 301–400 of 999
Effect of Telemedicine Interventions on Heart Failure Hospitalizations: A Randomized Trial
Ribeiro, E. G., Brant, L. C. C., Rezende, L. C., Bernal, R. T. I., Chequer, G., Temponi, B. V., Vilela, D. B., Buback, J. B., Lópes, R. D., Franco, T. B., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.036241 · Cited by 25
Heart Failure in Older Patients: An Update
Montalto, M., D'Ignazio, F., Camilli, S., Francesco, S. D., Fedele, M., Landi, F., & Gallo, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061982 · Cited by 26
High-density lipoprotein-mediated cardioprotection in heart failure
Jackson, A. O., Meng, J., Tang, H., & Yin, K. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09916-0 · Cited by 21
Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial
Cunningham, J. W., Ferreira, J. P., Deng, H., Anker, S. D., Byra, W. M., Cleland, J. G. F., Gheorghiade, M., Lam, C. S. P., Police, D. A. L., Mehra, M. R., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2019.12.009 · Cited by 21
Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
Cho, I., & Kang, S. (2021) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.900 · Cited by 20
Haider, L., Hugon‐Vallet, E., Constantin, J. P., Riad, Z., Sebbag, L., & Mewton, N. (2021) · Medical Sciences · doi:10.3390/medsci10010002 · Cited by 19
Henrysson, J., Thunström, E. Ö., Chen, X., Fu, M. L. X., & Basic, C. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14137 · Cited by 18
Getting ahead of the game: in-hospital initiation of HFrEF therapies
Biegus, J., Moayedi, Y., Saldarriaga, C., & Ponikowski, P. P. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac120 · Cited by 21
Mauro, C., Chianese, S., Cocchia, R., Arcopinto, M., Auciello, S., Capone, V., Carafa, M., Carbone, A., Caruso, G., Castaldo, R., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030846 · Cited by 30
Hyun, J., Cho, J. Y., Youn, J., Kim, D., Cho, D., Park, S. M., Jung, M., Cho, H., Park, S., Choi, J., et al. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0019 · Cited by 22
Rees, O., Wheen, P., & Anderson, L. J. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-2023-23.5.cardio1 · Cited by 30
Backelin, C. N., Fu, M. L. X., & Ljungman, C. E. A. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12644 · Cited by 19
Liu, L., Wu, P.-C., Chiu, M.-Y., Tu, P.-F., & Fang, C. (2020) · PubMed Central · doi:10.6515/acs.202003_36(2).20190812a · Cited by 19
Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy
Butler, J., Januzzi, J. L., & Rosenstock, J. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14042 · Cited by 20
Choi, H., & Shin, M. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.105 · Cited by 20
Kido, K., Bianco, C. M., Caccamo, M. A., Fang, W., & Sokos, G. G. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020983522 · Cited by 19
Illiano, S., Poirier, B., Minoletti, C., Pasquier, O., Riva, L., Chénedé, X., Menguy, I., Guillotel, M., Prigent, P., Claire, S. L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24716-2 · Cited by 20
Buda, V. O., Prelipcean, A., Cozma, D. C., Man, D. E., Negreș, S., Scurtu, A., Suciu, M., Andor, M., Danciu, C., Crișan, S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11072020 · Cited by 29
Reinhardt, S. W., Clark, K. A. A., Xin, X., Parzynski, C. S., Riello, R. J., Sarocco, P., Ahmad, T., & Desai, N. R. (2022) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.008069 · Cited by 21
Dunlay, S. M., Killian, J. M., Roger, V. L., Schulte, P. J., Blecker, S., Savitz, S. T., & Redfield, M. M. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.07.047 · Cited by 26
Cassano, V., Armentaro, G., Magurno, M., Aiello, V., Borrello, F., Miceli, S., Maio, R., Perticone, M., Marra, A. M., Cittadini, A., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1069828 · Cited by 21
Ducharme, A., Zieroth, S. R., Ahooja, V., Anderson, K., Andrade, J. G., Boivin‐Proulx, L., Ezekowitz, J. A., Howlett, J. G., Lepage, S., Leong, D., et al. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.04.022 · Cited by 25
Perera, K., Ademi, Z., Liew, D., & Zomer, E. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319878953 · Cited by 20
Kang, R., Nagoshi, T., Kimura, H., Tanaka, T. D., Yoshii, A., Inoue, Y., Morimoto, S., Ogawa, K., Minai, K., Ogawa, T., et al. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.08.012 · Cited by 20
Angiotensin-Neprilysin Inhibition in Black Americans
Berardi, C., Braunwald, E., Morrow, D. A., Mulder, H. S., Duffy, C. I., O’Brien, T. X., Ambrosy, A. P., Chakraborty, H., Velazquez, E. J., & DeVore, A. D. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.06.019 · Cited by 21
Self-citationKim, Y. S., Brar, S. K., Dalbo, N., Dey, A. K., Shah, S. P., Ganatra, S., & Dani, S. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07210-1 · Cited by 22
Grewal, D., Partow-Navid, R., Garcia, D., Coney, J., Fraser, G. E., Stoletniy, L. N., Sakr, A. E., Parwani, P. J., & Abramov, D. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.04.017 · Cited by 18
Dong, Y., Xu, Y., Ding, C., Yu, Z., Yu, Z., Xia, X., Chen, Y., & Jiang, X. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-21-386 · Cited by 21
Carrizales‐Sepúlveda, E. F., Ordaz‐Farías, A., Vargas-Mendoza, J. A., Vera‐Pineda, R., & Flores‐Ramírez, R. (2024) · Cardiac failure review · doi:10.15420/cfr.2023.20 · Cited by 21
Wearable technologies to predict and prevent and heart failure hospitalizations: a systematic review
Noci, F., Capodici, A., Nuti, S., Passino, C., Emdin, M., & Giannoni, A. (2025) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztaf079 · Cited by 24
Pang, Z., Pan, C., Yao, Z., Ren, Y., Tian, L., Cui, J., Liu, X., Zhang, L., & Chen, Y. (2021) · Medicine · doi:10.1097/md.0000000000025621 · Cited by 19
Wang, R., Ye, H., Zhao, Y., Wei, J., Wang, Y., Zhang, X., & Wang, L. (2022) · BMC Medicine · doi:10.1186/s12916-022-02682-w · Cited by 21
The Benefits of Sacubitril-Valsartan in Low Ejection Fraction Heart Failure
Aşkın, L., & Tanrıverdi, O. (2022) · Abant Medical Journal · doi:10.47493/abantmedj.1182158 · Cited by 18
Anthracyclines-Induced Cardiac Dysfunction: What Every Clinician Should Know
Ferrera, A., Fiorentini, V., Reale, S., Solfanelli, G., Tini, G., Barbato, E., Volpe, M., & Battistoni, A. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2405148 · Cited by 20
Unraveling Chronic Cardiovascular and Kidney Disorder through the Butterfly Effect
Bedo, D., Beaudrey, T., & Florens, N. (2024) · Diagnostics · doi:10.3390/diagnostics14050463 · Cited by 25
Drazner, M. H. (2019) · JAMA · doi:10.1001/jama.2019.12662 · Cited by 20
Charuel, É., Ménini, T., Bedhomme, S., Pereira, B., Piñol‐Domenech, N., Bouchant, S., Boussageon, R., Bœuf-Gibot, S., & Vaillant-Roussel, H. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.844 · Cited by 16
Mapelli, M., Salvioni, E., Martino, F. D., Mattavelli, I., Bonomi, A., Sassi, V., Gugliandolo, P., Vignati, C., Magini, A., Rovai, S., et al. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001018 · Cited by 20
Trask-Marino, A. L., Marino, B., Lancefield, T. F., See, E. J., May, C. N., Booth, L. C., Raman, J., & Lankadeva, Y. R. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2024 · Cited by 22
Anguita, M. P., Bayés‐Genís, A., Cepeda, J. M., Cinza‐Sanjurjo, S., Cosín, J., Leiro, M. C., Egocheaga, I., Escobar, C., Faraudo, M., García-Pinilla, J. M., et al. (2020) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(20)30016-9 · Cited by 24
Sepehrvand, N., Islam, S., Dover, D. C., Kaul, P., McAlister, F. A., Armstrong, P. W., & Ezekowitz, J. A. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.04.015 · Cited by 17
Contemporary Data on the Status and Medical Management of Acute Heart Failure
Bazmpani, M.-A., Papanastasiou, C. A., Kamperidis, V., Zebekakis, P. E., Karvounis, H. I., Kalogeropoulos, A. P., & Karamitsos, T. D. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01822-1 · Cited by 20
Essandoh, K., Teuber, J. P., & Brody, M. J. (2024) · Biochemical Society Transactions · doi:10.1042/bst20221296 · Cited by 17
Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024
Chinese Society of Cardiology, C. M. A., Chinese College of Cardiovascular Physician, Chinese Heart Failure Association of Chinese Medical Doctor Association, & Editorial Board of Chinese Journal of Cardiology (2025) · Cardiology Discovery · doi:10.1097/cd9.0000000000000146 · Cited by 50
Kondo, T., Jhund, P. S., Anand, I. S., Claggett, B. L., Desai, A. S., Docherty, K. F., Lam, C. S. P., Lefkowitz, M. P., Maggioni, A. P., Martínez, F. A., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.12.010 · Cited by 18
Optimally managing hyperkalemia in patients with cardiorenal syndrome
Wang, A. Y.-M. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz225 · Cited by 16
Li, J., Su, H., Zhu, Y. Y., Cao, Y., & Ma, X. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8642 · Cited by 20
Martyn, T., Faulkenberg, K. D., Albert, C. L., Il’Giovine, Z. J., Randhawa, V. K., Donnellan, E., Menon, V., Estep, J. D., Nissen, S. E., Tang, W. H. W., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.12.013 · Cited by 16
Aimo, A., Vergaro, G., Passino, C., & Clerico, A. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2021.1942782 · Cited by 20
Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure
Straw, S., McGinlay, M., Gierula, J., Lowry, J. E., Paton, M. F., Cole, C. A., Drozd, M., Koshy, A. O., Müllens, W., Cubbon, R. M., et al. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001231 · Cited by 18
Sex and Gender-Related Issues in Heart Failure
Romiti, G. F., Recchia, F., Zito, A., Visioli, G., Basili, S., & Raparelli, V. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.08.005 · Cited by 16
Women and diabetes: preventing heart disease in a new era of therapies
Galati, G., Sabouret, P., Germanova, O., & Bhatt, D. L. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.22 · Cited by 15
Krittayaphong, R., & Permsuwan, U. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01079-6 · Cited by 15
Sheng, Y., Ma, X., Liu, Y., Yang, X., & Sun, F. (2023) · Cardiology · doi:10.1159/000531217 · Cited by 16
NHC/ SHA 2023 Focused update of the 2019 guidelines for the management of heart failure
Habeeb, W. A., Tash, A. A., Elasfar, A., Almasood, A. S., Bakhsh, A., Elshaer, F., Ayoubi, F. A., Alghalaini, K., Alqaseer, M., Alhussein, M., et al. (2023) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1334 · Cited by 25
Heart Failure and All-Cause Hospitalizations in Patients With Heart Failure: A Meta-Analysis
Sayed, A. A., ElRefaei, M., Awad, K., Salah, H., Mandrola, J. M., & Foy, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.46684 · Cited by 17
Rajzer, P., & Biegus, J. (2025) · Heart Failure Reviews · doi:10.1007/s10741-024-10471-1 · Cited by 21
Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
Cuthbert, J. J., Pellicori, P., & Clark, A. L. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s234772 · Cited by 18
de la Espriella, R., Bayés‐Genís, A., Morillas, H., Bravo, R., Vidal, V., Núñez, E., Santas, E., Miñana, G., Sanchís, J. M., Fácila, L., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12965 · Cited by 22
Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials
Huang, Y., Zhang, Y., Ma, L., Zhou, H., Fang, C., & Chen, C. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001049 · Cited by 16
Sabouret, P. F., Attias, D., Beauvais, C., Berthelot, E., Bouleti, C., Gibault‐Genty, G., Galat, A., Hanon, O., Hulot, J., Isnard, R., et al. (2021) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2021.05.004 · Cited by 21
Stewart, R., Kirby, A. C., White, H. D., Marschner, S. L., West, M., Thompson, P. L., SULLIVAN, D. R., Janus, E. D., Hunt, D. U., Kritharides, L., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024616 · Cited by 18
Vasques‐Nóvoa, F., Ferreira, J. P., Marques, P. S., Neves, J. S., Vale, C., Ribeirinho-Soares, P., Marques, J. A. D. C., Martins, S., Guimarães, J. T., Barros, A. S., et al. (2022) · Cytokine · doi:10.1016/j.cyto.2022.156053 · Cited by 15
Tillman, F., Kim, J., Makhlouf, T. K., & Osae, L. (2019) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944719840192 · Cited by 18
Wang, R., Ye, H., Ma, L., Wei, J., Wang, Y., Zhang, X., & Wang, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.890481 · Cited by 14
Pathophysiology-Based Management of Acute Heart Failure
Falco, L., Martucci, M. L., Valente, F., Verrengia, M., Pacileo, G., & Masarone, D. (2023) · Clinics and Practice · doi:10.3390/clinpract13010019 · Cited by 21
Böhm, M., Abdin, A., Slawik, J., Mahfoud, F., BORER, J. S., Ford, I., Swedberg, K. B., Tavazzi, L., Batailler, C., & Komajda, M. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2870 · Cited by 15
Kasprzak, J. D., Gorczyca-Głowacka, I., Sobczak, M., Barylski, M., Dróżdż, J., Filipiak, K. J., Kapłon‐Cieślicka, A., Lelonek, M., Mamcarz, A., Ochijewicz, D., et al. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0110 · Cited by 26
Lee, V., Zheng, Q., Toh, D., Pua, C. J., Bryant, J., Lee, C., Cook, S. A., Butler, J., Díez, J., Richards, M., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1248468 · Cited by 16
Tsutsui, H., Momomura, S., Saito, Y., Ito, H., Yamamoto, K., Sakata, Y., Ohishi, T., Kumar, P., & Kitamura, T. (2023) · Circulation Journal · doi:10.1253/circj.cj-23-0174 · Cited by 15
Bhatt, A. S., Fonarow, G. C., Greene, S. J., Holmes, D. N., Alhanti, B., DeVore, A. D., Butler, J., Heidenreich, P. A., Huang, J., Kittleson, M. M., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.09.005 · Cited by 16
Self-citationStolfo, D., Benson, L., Lindberg, F., Dahlström, U., Käck, O., Sinagra, G., Lund, L. H., & Savarese, G. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3404 · Cited by 16
Acute Heart Failure and Non-Ischemic Cardiomyopathies: A Comprehensive Review and Critical Appraisal
Manzi, L., Buongiorno, F., Narciso, V., Florimonte, D., Forzano, I., Castiello, D. S., Sperandeo, L., Paolillo, R., Verde, N., Spinelli, A. M., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15050540 · Cited by 20
Sacubitril/valsartan in chronic kidney disease, the nephrologist point of view
Quiroga, B., de Santos, A., Sapiencia, D., Catala, Y. S., & Chiva, V. Á. (2019) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2019.12.002 · Cited by 14
Kuang, H., Huang, X., Zhou, Z., Cheng, X., & Xu, G. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174288 · Cited by 16
Teo, Y. N., Teo, Y. H., Syn, N. L. X., Yoong, C. S. Y., Cheong, A. J. Y., Wee, C. F., Lim, Y. C., Lee, C., Yeo, T., Chai, P., et al. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01098-3 · Cited by 14
Pitt, B., Ferreira, J. P., & Zannad, F. M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab717 · Cited by 14
Oh, J., Lee, J.-M., Lee, H. J., Hwang, J., Lee, C. H., Cho, Y., Park, H., Yoon, H., Chung, J.-W., Kim, H., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13940 · Cited by 14
Shen, M., Zheng, C., Chen, L., Li, M., Huang, X., He, M., Liu, C.-Y., Lin, H., Liao, W., Bin, J., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114569 · Cited by 15
Sim, D., Lin, W., Sindone, A. P., Yingchoncharoen, T., Prameswari, H. S., Ghazi, A. M., Pin, L. C., Teo, L. L. Y., Aw, T. C., Agbayani, M. F., et al. (2023) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2022.42 · Cited by 14
Determinants of maximal dose titration of sacubitril/valsartan in clinical practice
Martens, P., Verluyten, L., de Broek, H. V., Somers, F., Dauw, J., Dupont, M., & Müllens, W. (2019) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2019.1686226 · Cited by 14
Dani, S. S., Ganatra, S., & Vaduganathan, M. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.08.067 · Cited by 18
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy
Čikeš, M., Brugts, J. J., Claggett, B. L., Jorde, U. P., Milicić, D., Planinc, I., Ruschitzka, F. T., Uriel, N. Y., Kulac, I. J., Jakuš, N., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102657 · Cited by 15
Charkviani, M., Krisanapan, P., Thongprayoon, C., Craici, I. M., & Cheungpasitporn, W. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.10.008 · Cited by 14
Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction
Nasrallah, D., Abdelhamid, A., Tluli, O., Al-Haneedi, Y., Dakik, H. A., & Eid, A. H. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107210 · Cited by 17
Cardiac Myosin Activation for the Treatment of Systolic Heart Failure
Bernier, T. D., & Buckley, L. F. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000929 · Cited by 13
Pandey, A. C., Jer, D., Kuo, R. S., Yoo, D. H., Christophy, A. C., Mohan, R. C., Srivastava, A. V., & Heywood, J. T. (2020) · Clinical Cardiology · doi:10.1002/clc.23509 · Cited by 12
Campal, J. M. R., Castillo, H. D., Rivera, B. A., Bitria, C. D. J., Urquía, M. T., Borque, P. S., Blanco, Á. M., Calero, L. B., Sánchez, D. M., & Fernández, J. T. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0009 · Cited by 14
Nuechterlein, K., AlTurki, A., Ni, J., Martínez‐Sellés, M., Martens, P., Russo, V., Backelin, C. N., & Huynh, T. T. (2021) · CJC Open · doi:10.1016/j.cjco.2021.09.009 · Cited by 14
Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis
Barbosa, C. V., Lang, H., Melk, A., & Schmidt, B. M. W. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac001 · Cited by 18
Lee, K., Noh, J. H., Park, S., Choi, K. M., Kang, S., Won, K. C., Cho, H., Moon, M. K., & Korean Society of Heart Failure (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0420 · Cited by 14
Sacubitril/valsartan in COVID-19 patients: the need for trials
Acanfora, D., Ciccone, M. M., Scicchitano, P., Acanfora, C., & Casucci, G. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa044 · Cited by 13
Shaddy, R. E., Gong, J., Garito, T., Solar‐Yohay, S., Zhang, S., PRESCOTT, M. F., Bonnet, D., Kantor, P. F., Burch, M., Mao, C. Y., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15326 · Cited by 13
Przytuła, N., Podolec, J., Przewłocki, T., Podolec, P. S., & Kabłak-Ziembicka, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211003 · Cited by 14
Tereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Михайловна, Г. Е., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-3-6-76 · Cited by 13
Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure
Iovanovici, D. C., BUNGAU, S. G., Vesa, C. M., Moisi, M. I., Babeş, E. E., Ţiţ, D. M., Horvath, T., Behl, T., & Rus, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911336 · Cited by 14
Fabiani, I., Pugliese, N. R., Pedrizzetti, G., Tonti, G., Castiglione, V., Chubuchny, V., Taddei, C., Gimelli, A., Punta, L. D., Balletti, A., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14346 · Cited by 14
Narayan, S. I., Terre, G. V., Amin, R., Shanghavi, K. V., Chandrashekar, G. S., Ghouse, F., Ahmad, B. A., Gowri, N. S., Satram, C., Majid, H. A., et al. (2023) · Cureus · doi:10.7759/cureus.45719 · Cited by 18
Si, J., Ding, Z., Hu, Y., Zhang, X., Zhang, Y., Cao, H., & Liu, Y. (2023) · Journal of Cardiology · doi:10.1016/j.jjcc.2023.09.012 · Cited by 12
Pagnesi, M., Vilamajó, O. A. G., Meiriño, A., Dumont, C. A., Mebazaa, A., Davison, B. A., Adamo, M., Arrigo, M., Barros, M., Biegus, J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3174 · Cited by 13
Metadata
- Authors
- Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (E.J.V.); the Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston (D.A.M., E.B.); Duke Clinical Research Institute, Duke University, Durham, NC (A.D.D.); Novartis Pharmaceuticals, East Hanover, NJ (C.I.D., K.M., R.R.); and the Division of Cardiology, Permanente...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-07
- Volume
- 380
- Issue
- 6
- Pages
- 539-548
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899841238
- Cited by
- 1,260
- References
- 16
- Citations by year
- 2026: 74 · 2025: 139 · 2024: 136 · 2023: 215 · 2022: 199 · 2021: 189 · 2020: 171 · 2019: 128
- FWCI
- 93.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- acute decompensated heart failure, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, NT-proBNP, renal function, hyperkalemia, angioedema, symptomatic hypotension, drug safety, hospitalization, hemodynamic stabilization, natriuretic peptides
- MeSH terms
- Valsartan, Acute Disease, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiac Output, Low, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Humans, Male, Middle Aged, Peptide Fragments, Stroke Volume, Tetrazoles, Neprilysin, Natriuretic Peptide, Brain, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.